4 ms·
The patent and the marketing didn't make hydrocodone less viable as an alternative. I mean, the doctors can see that information coming from the company can be
by maxerickson 11y ago
The patent and the marketing didn't make hydrocodone less viable as an alternative.
I mean, the doctors can see that information coming from the company can be problematic and be cautious of it. I guess they ideally shouldn't have to be, but that's not the world.
Personally, I'd be fine dismantling Purdue for something like this. We need to start recognizing that large institutions make mistakes for reasons that can't be fixed.
- vinceguidry 11y agoI'm not opposed to that, but you also need to fix broken systems, otherwise the problem will recur.
- maxerickson 11y agoTo me the big flaw is that FDA approval and the associated studies were enough to drive the prescriptions. It would be pretty easy for the healthcare system to systematically run their own comparative studies on new drugs (during the course of normal care). There's some ethical mumbo jumbo around best possible care to look at, but I think being cautious about unfamiliar products is probably a nice offset to those concerns. I find myself thinking back to this discussion: https://news.ycombinator.com/item?id=11627213 https://news.ycombinator.com/item?id=11627213 Where I quoted Peter Pronovost (the checklist guy) saying: The fundamental problem with the quality of American medicine is that we’ve failed to view delivery of health care as a science. The tasks of medical science fall into three buckets. One is understanding disease biology. One is finding effective therapies. And one is ensuring those therapies are delivered effectively. That third bucket has been almost totally ignored by research funders, government, and academia. It’s viewed as the art of medicine. This is literally a case of boxes 1 and 2 being checked, with little attention to box 3.